A detailed history of Geode Capital Management, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,848,133 shares of CRNX stock, worth $99.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,848,133
Previous 1,678,387 10.11%
Holding current value
$99.7 Million
Previous $75.2 Million 25.58%
% of portfolio
0.01%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$43.83 - $54.98 $7.44 Million - $9.33 Million
169,746 Added 10.11%
1,848,133 $94.4 Million
Q2 2024

Aug 09, 2024

BUY
$42.12 - $51.91 $11.7 Million - $14.4 Million
276,984 Added 19.76%
1,678,387 $75.2 Million
Q1 2024

May 13, 2024

BUY
$34.76 - $46.81 $1.69 Million - $2.28 Million
48,731 Added 3.6%
1,401,403 $65.6 Million
Q4 2023

Feb 13, 2024

BUY
$25.62 - $37.07 $2.13 Million - $3.08 Million
82,998 Added 6.54%
1,352,672 $48.1 Million
Q3 2023

Nov 13, 2023

BUY
$15.97 - $30.59 $4.51 Million - $8.63 Million
282,184 Added 28.58%
1,269,674 $37.8 Million
Q2 2023

Aug 11, 2023

BUY
$15.73 - $23.6 $513,269 - $770,068
32,630 Added 3.42%
987,490 $17.8 Million
Q1 2023

May 15, 2023

BUY
$15.31 - $21.1 $514,875 - $709,593
33,630 Added 3.65%
954,860 $15.3 Million
Q4 2022

Feb 13, 2023

BUY
$15.49 - $19.05 $590,711 - $726,471
38,135 Added 4.32%
921,230 $16.9 Million
Q3 2022

Nov 14, 2022

BUY
$18.11 - $22.37 $582,363 - $719,352
32,157 Added 3.78%
883,095 $17.3 Million
Q2 2022

Aug 12, 2022

BUY
$16.49 - $27.64 $1.82 Million - $3.06 Million
110,553 Added 14.93%
850,938 $15.9 Million
Q1 2022

May 13, 2022

BUY
$17.15 - $28.31 $714,246 - $1.18 Million
41,647 Added 5.96%
740,385 $16.3 Million
Q4 2021

Feb 11, 2022

BUY
$19.35 - $28.41 $3.46 Million - $5.08 Million
178,741 Added 34.37%
698,738 $19.9 Million
Q3 2021

Nov 12, 2021

BUY
$16.88 - $25.23 $188,650 - $281,970
11,176 Added 2.2%
519,997 $10.9 Million
Q2 2021

Aug 13, 2021

BUY
$15.9 - $21.15 $2.09 Million - $2.78 Million
131,387 Added 34.81%
508,821 $9.59 Million
Q1 2021

May 12, 2021

BUY
$13.3 - $17.55 $743,908 - $981,624
55,933 Added 17.4%
377,434 $5.77 Million
Q4 2020

Feb 12, 2021

BUY
$12.08 - $17.46 $117,465 - $169,781
9,724 Added 3.12%
321,501 $4.54 Million
Q3 2020

Nov 13, 2020

SELL
$13.62 - $17.66 $65,144 - $84,467
-4,783 Reduced 1.51%
311,777 $4.89 Million
Q2 2020

Aug 13, 2020

BUY
$13.04 - $23.23 $2.38 Million - $4.24 Million
182,541 Added 136.21%
316,560 $5.55 Million
Q1 2020

May 14, 2020

BUY
$11.52 - $26.46 $64,627 - $148,440
5,610 Added 4.37%
134,019 $1.97 Million
Q4 2019

Feb 13, 2020

BUY
$15.24 - $25.09 $102,580 - $168,880
6,731 Added 5.53%
128,409 $3.22 Million
Q3 2019

Nov 12, 2019

BUY
$14.91 - $25.01 $31,952 - $53,596
2,143 Added 1.79%
121,678 $1.83 Million
Q2 2019

Aug 14, 2019

BUY
$21.48 - $27.71 $630,287 - $813,094
29,343 Added 32.53%
119,535 $2.99 Million
Q1 2019

May 14, 2019

BUY
$21.07 - $29.31 $306,336 - $426,138
14,539 Added 19.22%
90,192 $2.05 Million
Q4 2018

Feb 13, 2019

BUY
$22.4 - $35.39 $348,051 - $549,889
15,538 Added 25.85%
75,653 $2.27 Million
Q3 2018

Nov 13, 2018

BUY
$22.66 - $36.8 $1.36 Million - $2.21 Million
60,115 New
60,115 $1.72 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.9B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.